FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Greetings and welcome to the X4 Pharmaceuticals fourth quarter and full year 2024 financial and operating results conference call. (Operator Instructions) and it is now my pleasure to turn to your ...

WASHINGTON, DC – The U.S. Department of Justice has charged Indian chemical manufacturer Vasudha Pharma Chem Limited (VPC) ...

Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.

As Robert F. Kennedy Jr. settles into his role as President Donald Trump’s health secretary, one major promise he’s made is ...

MM+M Agency 100 issue is nominated for Best Single Issue of a Tabloid/Newspaper/Magazine for a brand with revenue between $3 ...

The PMCPA has dug into the industry’s LinkedIn activities once again. | The PMCPA has dug into the industry’s LinkedIn ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

For some Big Pharma companies, sales in China contributed to more than 10 percent of global sales, making China a top market ...

Levies on foreign goods including lumber and pharmaceuticals could come after April 2, president says. Oil futures extended gains to a fourth session, lifted by the U.S. threat to impose import ...

With the popular social media app once again at risk of going dark, there are best practices pharma brands can use on other ...

In this episode of The Top Line, sponsored by PatientPoint, Andrew Schultz, President of PatientPoint Precision, discusses ...